Bharat Parenterals' Q1 FY 2026-27 Quarterly Results

Result Summary

• Bharat Parenterals Ltd reported a 8.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 19.0%.
• Its expenses for the quarter were down by 13.7% QoQ and 15.9% YoY.
• The net profit decreased 56.4% QoQ and increased 309.2% YoY.
• The earnings per share (EPS) of Bharat Parenterals Ltd declined at 5.17 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bharat Parenterals Ltd is a pharmaceutical company primarily engaged in the manufacturing and marketing of parenteral formulations, which are medications administered by injection. The company is positioned within the pharmaceutical industry, a sector known for its significant role in healthcare by providing essential medicines and treatment solutions. As of the last known update, there is no specific information available regarding recent major developments or strategic changes within Bharat Parenterals Ltd. The company continues to operate in a competitive market characterized by ongoing research and development, regulatory challenges, and a continuous demand for healthcare solutions.

Revenue

In the first quarter of the fiscal year 2027 (Q1FY27), Bharat Parenterals Ltd reported total income of ₹94.85 crores. This figure represents an 8.1% decline from the previous quarter (Q4FY26), where total income was ₹103.25 crores. Compared to the same quarter in the previous year (Q1FY26), total income decreased by 19.0% from ₹117.06 crores. These figures indicate a downward trend in revenue on both a quarterly and annual basis. The decline in revenue could be attributed to various factors, including market dynamics, competitive pressures, or changes in demand for the company's products, although specific reasons are not detailed in the available data.

Profitability

Bharat Parenterals Ltd reported a loss before tax of ₹1.49 crores in Q1FY27, which is an improvement from the loss of ₹8.37 crores in Q4FY26. However, this contrasts with a positive profit before tax of ₹2.55 crores in Q1FY26. The year-over-year comparison shows a significant decline of 158.4% in profit before tax. After accounting for taxes, the company reported a net loss (profit after tax) of ₹3.56 crores in Q1FY27, a reduction from the net loss of ₹8.16 crores in the previous quarter but a noticeable increase from the net loss of ₹0.87 crores in Q1FY26. The earnings per share (EPS) for Q1FY27 was negative at ₹-5.17, which improved from ₹-11.84 in the prior quarter but worsened from ₹-1.27 in the same quarter of the previous year.

Operating Metrics

The financial data for Bharat Parenterals Ltd indicates a reduction in total expenses, which were ₹96.34 crores in Q1FY27, down by 13.7% from ₹111.63 crores in Q4FY26 and 15.9% from ₹114.51 crores in Q1FY26. This reduction in expenses aligns with the overall decrease in revenue, yet the company's operating efficiency metrics, such as profit margins, remain under pressure due to the losses reported in the current and previous quarters. The tax expense in Q1FY27 was ₹2.07 crores, contrasting notably with a tax benefit of ₹-0.21 crores in Q4FY26 and a tax expense of ₹3.42 crores in Q1FY26. These variations in tax expenses reflect changes in the company's taxable income and potential adjustments in tax strategies or liabilities.

Overall, the financial data for Bharat Parenterals Ltd highlights fluctuations in revenue, profitability, and operating expenses, providing a snapshot of the company's financial health during the period analyzed.